Difei Yang
Stock Analyst at Mizuho
(2.14)
# 2,909
Out of 5,124 analysts
33
Total ratings
31.03%
Success rate
11.79%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $1.55 | +29.03% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $13.12 | +1,424.39% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $0.82 | +4,521.18% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $725 | $9.16 | +7,814.85% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $23.39 | +122.32% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $21.31 | +650.82% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $7.35 | +90.48% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $43.42 | +1,109.12% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.22 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $13.57 | +106.34% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.26 | +2,122.22% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $1.55
Upside: +29.03%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $13.12
Upside: +1,424.39%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $0.82
Upside: +4,521.18%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $9.16
Upside: +7,814.85%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $23.39
Upside: +122.32%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $21.31
Upside: +650.82%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $7.35
Upside: +90.48%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $43.42
Upside: +1,109.12%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.22
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $13.57
Upside: +106.34%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.26
Upside: +2,122.22%